Abstract Number: 1086 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease. Regulatory T (Treg) cells and T helper type 17 (Th17) cells play opposite roles…Abstract Number: 2785 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Background/Purpose: Both the IL-12 and IL-23 pathways have been linked to SLE pathogenesis. The anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST), which is approved for psoriasis,…Abstract Number: 744 • 2015 ACR/ARHP Annual Meeting
Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous
Background/Purpose: The clinical presentation may be different between adult-onset SLE (aSLE) and childhood-onset SLE (cSLE). The profile of cytokine may the clarify of SLE pathophysiology. The…Abstract Number: 2735 • 2014 ACR/ARHP Annual Meeting
Association of a-Kinase Anchoring Protein-79 (AKAP79) to PKC Mediates Inhibition of IL2 Transcription and Erk Activation in T Cells
Background/Purpose A-Kinase anchoring Protein AKAP79 associates to and regulates the activity of PKA, PKC and calcineurin, key regulators of T cell activation. We have previously…Abstract Number: 2685 • 2014 ACR/ARHP Annual Meeting
Ten-Eleven Translocation 2 Protein Down-Regulates DNA Methylation of Interleukin-17A Promoter and Induces Its Expression in CD4+t Cells of Patients with Systemic Lupus Erythematosus
Background/Purpose: Recent evidence indicates that IL-17A plays a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE). SLE patients have…Abstract Number: 634 • 2013 ACR/ARHP Annual Meeting
IL-21/IL-21R Interaction On Lymphocyte Subsets From Lupus Patients
Background/Purpose: We have previously shown that IL-21 promotes autoimmunity in a mouse model of lupus through both CD4 and B cell intrinsic mechanisms. Recent studies…Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…Abstract Number: 664 • 2012 ACR/ARHP Annual Meeting
Estrogen Upregulates Interleukin-21 Production of Clusters of Differentiation 4 Positive T Lymphocytes in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease in which various organs and tissues are damaged through abnormal immune responses mediated by tissue-binding autoantibodies…Abstract Number: 673 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Background/Purpose: SLE is a complex autoimmune disease marked by autoantibody production and immune dysregulation. Identification of at-risk populations is essential to minimize morbidity and mortality…Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…
ACR Meeting Abstracts